Evidence map›Paper›PMID 41630988›Full record

ArticleMolecular therapy. Nucleic acids2026

Identification and functional validation of intracellular protein partners of phosphorothioate splice-switching oligonucleotides using AP-MS.

Aris Gaci, Grégory Menchon, Johanna Bruce, Virginie Salnot, Rémy Pedeux, Aurélie Goyenvalle

Abstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aris GaciUniversité Paris-Saclay, UVSQ, Inserm, END-ICAP, 78000 Versailles, France.
Grégory MenchonUniversité de Rennes, OSS, Inserm, UMR_S 1242, 35000 Rennes, France.
Johanna Bruce3P5 Proteom'IC facility, Université de Paris, Institut Cochin, INSERM, CNRS, 75014 Paris, France.
Virginie Salnot3P5 Proteom'IC facility, Université de Paris, Institut Cochin, INSERM, CNRS, 75014 Paris, France.
Rémy PedeuxUniversité de Rennes, OSS, Inserm, UMR_S 1242, 35000 Rennes, France.
Aurélie GoyenvalleUniversité Paris-Saclay, UVSQ, Inserm, END-ICAP, 78000 Versailles, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellular uptake and intracellular distribution of phosphorothioate-modified antisense oligonucleotides (PS-ASOs) are mediated by protein interactions. While several PS-ASOs-binding proteins have been identified, mainly using gapmer designs with 2'-O-methoxyethyl (2'MOE) modifications, less is known about protein partners of splice-switching oligonucleotides (SSOs) with alternative ribose modifications. Here, using affinity purification mass spectrometry (AP-MS), we identified the intracellular protein partners of PS-SSOs of the same sequence with three distinct ribose modifications: tricyclo-DNA (tcDNA), locked nucleic acid (LNA), and 2'MOE. Interestingly, we found previously reported PS interactors, such as GRSF1, NONO, and NCL, as well as uncharacterized protein partners. Four shared interactors identified in this study, ERC1, SPIRE1, THRAP3, and GOLGA2, were selected based on functional relevance and tested for their impact on exon skipping efficacy using PS-SSOs targeting the human Duchenne muscular dystrophy (DMD) transcript. RNA interference-mediated knockdown of each protein led to a reduction of exon skipping efficiency, suggesting that these proteins may contribute to PS-ASOs activity regardless of their sugar modifications. Overall, our results provide a set of intracellular protein interactors of different PS-ASOs, representing a valuable resource to explore mechanisms underlying their activity and offering potential leads for the optimization of oligonucleotide therapeutics.

Indexed as

affinity purification mass spectrometryantisense oligonucleotidesAP-MSASOsDMDDuchenne muscular dystrophyexon skippingMT: oligonucleotides: therapies and applicationsphosphorothioateprotein-oligonucleotide interactionPSRNA interferencesiRNAssplice-switching oligonucleotidesSSOs

Identifiers

PMID41630988
PMCPMC12860984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.